ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+4.74%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$485M
AUM Growth
+$485M
(-19%)
Cap. Flow
-$74.8M
Cap. Flow
% of AUM
-15.41%
Top 10 Holdings %
Top 10 Hldgs %
49.77%
Holding
309
New
41
Increased
54
Reduced
66
Closed
104
Top Buys
| 1 |
Inhibikase Therapeutics
IKT
|
$16.6M |
| 2 |
Zai Lab
ZLAB
|
$13.4M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$10.1M |
| 4 |
ABVX
Abivax
ABVX
|
$7.26M |
| 5 |
AVR
Anteris Technologies Global Corp. Common Stock
AVR
|
$5.88M |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$26.7M |
| 2 |
Cytokinetics
CYTK
|
$23.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$21.1M |
| 4 |
Ascendis Pharma
ASND
|
$12.4M |
| 5 |
Immunovant
IMVT
|
$8.53M |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Financials | 3.47% |
| 3 | Communication Services | 1.36% |
| 4 | Utilities | 0.04% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Axsome Therapeutics
AXSM
$6.05B
| $1.66M | 0.33% |
19,661
+19,061
| +3,177% | +$1.61M |
|
52
Soleno Therapeutics
SLNO
$3.6B
| $1.66M | 0.33% |
36,830
+26,830
| +268% | +$1.21M |
|
53
KALA BIO
KALA
$78.8M
| $1.53M | 0.31% |
220,373
-85,694
| -28% | -$595K |
|
|
AACT
54
Ares Acquisition Corporation II
AACT
$706M
| $1.53M | 0.3% |
138,966
| – | – |
|
55
Insmed
INSM
$28.8B
| $1.52M | 0.3% |
21,974
+18,340
| +505% | +$1.27M |
|
|
CDMO
56
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $1.48M | 0.3% |
+120,000
| New | +$1.48M |
|
|
SLRN
57
DELISTED
ACELYRIN
SLRN
| $1.4M | 0.28% |
444,967
+391,467
| +732% | +$1.23M |
|
|
VRNA
58
Verona Pharma
VRNA
$9.16B
| $1.35M | 0.27% |
29,100
+19,100
| +191% | +$887K |
|
59
Regenxbio
RGNX
$451M
| $1.32M | 0.26% |
170,129
-398,879
| -70% | -$3.08M |
|
|
PSTX
60
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $1.29M | 0.26% |
+134,109
| New | +$1.29M |
|
|
61
Royalty Pharma
RPRX
$15.6B
| $1.27M | 0.25% |
49,963
-1,046,703
| -95% | -$26.7M |
|
|
CTNM
62
Contineum Therapeutics
CTNM
$293M
| $1.2M | 0.24% |
82,234
+73,267
| +817% | +$1.07M |
|
|
ACOG
63
Alpha Cognition Inc. Common Stock
ACOG
$134M
| $1.2M | 0.24% |
+204,348
| New | +$1.2M |
|
64
Geron
GERN
$893M
| $1.2M | 0.24% |
337,676
-219,483
| -39% | -$777K |
|
65
Lexeo Therapeutics
LXEO
$259M
| $1.12M | 0.22% |
169,505
+112,339
| +197% | +$739K |
|
66
Eli Lilly
LLY
$657B
| $1.04M | 0.21% |
1,350
+200
| +17% | +$154K |
|
67
iBio
IBIO
$16.1M
| $1.02M | 0.2% |
415,606
-60,606
| -13% | -$148K |
|
68
iTeos Therapeutics
ITOS
| $1.01M | 0.2% |
131,599
-245,138
| -65% | -$1.88M |
|
69
Kezar Life Sciences
KZR
$28.9M
| $991K | 0.2% |
147,404
-1,190,869
| -89% | -$8M |
|
70
OmniAb
OABI
$230M
| $985K | 0.2% |
278,108
-1,059,194
| -79% | -$3.75M |
|
71
Regeneron Pharmaceuticals
REGN
$61.5B
| $969K | 0.19% |
1,361
+490
| +56% | +$349K |
|
72
Structure Therapeutics
GPCR
$1.11B
| $958K | 0.19% |
+35,319
| New | +$958K |
|
73
Beam Therapeutics
BEAM
$1.66B
| $950K | 0.19% |
38,312
-5,588
| -13% | -$139K |
|
74
MoonLake Immunotherapeutics
MLTX
$3.54B
| $944K | 0.19% |
17,424
-6,033
| -26% | -$327K |
|
75
Pfizer
PFE
$141B
| $930K | 0.19% |
35,050
-900
| -3% | -$23.9K |
|